Atrial fibrillation: Guiding lessons from epidemiology

Cardiology Clinics

Volumn 22, Issue 1, 2004, Pages 1-8

  Crystal, Eugene ^a   Connolly, Stuart J ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; TRANDOLAPRIL;

CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART INFARCTION; HOLTER MONITORING; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; ONSET AGE; PREVALENCE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SCREENING; SEASONAL VARIATION; VALVULAR HEART DISEASE;

EID: 1642477499     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8651(03)00118-8     Document Type: Review

References (55)

1. Fuster V., Ryden L.E., Asinger R.W., Cannom D.S., Crijns H.J., Frye R.L., et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation). Developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation. 104:2001;2118-2150.
2. Domanski M.J. The epidemiology of atrial fibrillation. Coron Artery Dis. 6:1995;95-100.
3. Ostrander L.D., Brandt R.L., Kjelsberg M.O., Epstein F.H. Electrocardiographic findings among the adult population of a total natural community, Tecumseh, Michigan. Circulation. 31:1965;888-898.
4. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 22:1991;983-988.
5. Furberg C.D., Psaty B.M., Manolio T.A., Gardin J.M., Smith V.E., Rautaharju P.M. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol. 74:1994;236-241.
6. Kannel W.B., Wolf P.A., Benjamin E.J., Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 82:1998;2N-9N.
7. Benjamin E.J., Levy D., Vaziri S.M., D'Agostino R.B., Belanger A.J., Wolf P.A. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 271:1994;840-844.
8. Krahn A.D., Manfreda J., Tate R.B., Mathewson F.A., Cuddy T.E. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 98:1995;476-484.
9. Wattigney W.A., Mensah G.A., Croft J.B. Increased atrial fibrillation mortality: United States, 1980-1998. Am J Epidemiol. 155:2002;819-826.
10. Stewart S., Hart C.L., Hole D.J., McMurray J.J. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart. 86:2001;516-521.
11. Humphries K.H., Kerr C.R., Connolly S.J., Klein G., Boone J.A., Green M., et al. New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation. 103:2001;2365-2370.
12. Wenger N.K. Coronary heart disease: an older woman's major health risk. BMJ. 315:1997;1085-1090.
13. Go A.S., Hylek E.M., Phillips K.A., Chang Y., Henault L.E., Selby J.V., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 285:2001;2370-2375.
14. Frost L., Johnsen S.P., Pedersen L., Husted S., Engholm G., Sorensen H.T., et al. Seasonal variation in hospital discharge diagnosis of atrial fibrillation: a population-based study. Epidemiology. 13:2002;211-215.
15. Prystowsky E.N., Katz A. Atrial fibrillation. Topol E.J. Textbook of cardiovascular medicine. 1998;1661-1689 Lippincott-Rane Publishers, Philadelphia.
16. Lewis T. Auricular fibrillation and its relationship clinical irregularity of the heart. Heart. I:1910;306-372.
17. Lok N.S., Lau C.P. Presentation and management of patients admitted with atrial fibrillation: a review of 291 cases in a regional hospital. Int J Cardiol. 48:1995;271-278.
18. Godtfredsen J. Atrial fibrillation: cause and prognosis - a follow up study of 1212 cases. Kulbertus H.A., Olssen S.B., Schlepper M. Atrial fibrillation. 1982;134-145 AB Hassle, Molndal, Sweden.
19. Kunishige H., Otake M. Atrial fibrillation: a study based on a fixed adult population and prediction by prefibrillatory electrocardiographic findings. Jpn Circ J. 36:1972;785-796.
20. Godtfredsen J. Atrial fibrillation: etiology, course and prognosis. A follow-up study of 1212 cases. In: Atrial fibrillation. Copenhagen, Denmark; 1975.
21. Maru M. Atrial fibrillation and embolic complications. East Afr Med J. 74:1997;3-5.
22. Takahashi N., Seki A., Imataka K., Fujii J. Clinical features of paroxysmal atrial fibrillation. An observation of 94 patients. Jpn Heart J. 22:1981;143-149.
23. Koide Y., Yotsukura M., Sakata K., Yoshino H., Ishikawa K. Investigation of the predictors of transition to persistent atrial fibrillation in patients with paroxysmal atrial fibrillation. Clin Cardiol. 25:2002;69-75.
24. Frost L., Engholm G., Moller H., Husted S. Decrease in mortality in patients with a hospital diagnosis of atrial fibrillation in Denmark during the period 1980-1993. Eur Heart J. 20:1999;1592-1599.
25. Stewart S., MacIntyre K., MacLeod M.M., Bailey A.E., Capewell S., McMurray J.J. Trends in hospital activity, morbidity and case fatality related to atrial fibrillation in Scotland, 1986-1996. Eur Heart J. 22:2001;693-701.
26. Dialy B., Lehmann M.H., Schumacher D.N., Steinman R.T., Meissner M.D. Hospitalization for arrhythmias in the United States: importance of atrial fibrillation. [abstract] J Am Coll Cardiol. 19:1992;41A.
27. Viskin S., Golovner M., Malov N., Fish R., Alroy I., Vila Y., et al. Circadian variation of symptomatic paroxysmal atrial fibrillation. Data from almost 10,000 episodes. Eur Heart J. 20:1999;1429-1434.
28. Kupari M., Koskinen P. Seasonal variation in occurrence of acute atrial fibrillation and relation to air temperature and sale of alcohol. Am J Cardiol. 66:1990;1519-1520.
29. Psaty B.M., Manolio T.A., Kuller L.H., Kronmal R.A., Cushman M., Fried L.P., et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 96:1997;2455-2461.
30. Savelieva I., Camm A.J. Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. J Interv Card Electrophysiol. 4:2000;369-382.
31. Nuernberg M., Hansen S., Steinbach K. A lower incidence of permanent atrial fibrillation in single-lead VDD versus two-lead DDD pacing in the treatment of AV block. [abstract] Circulation. 106:2002;624-625.
32. Savelieva I., Camm A.J. Silent atrial fibrillation - another Pandora's box. Pacing Clin Electrophysiol. 23:2000;145-148.
33. Kerr C., Boone J., Connolly S., Greene M., Klein G., Sheldon R., et al. Follow-up of atrial fibrillation: the initial experience of the Canadian Registry of Atrial Fibrillation. Eur Heart J. 17:(Suppl C):1996;48-51.
34. Kopecky S.L., Gersh B.J., McGoon M.D., Whisnant J.P., Holmes D.R. Jr., Ilstrup D.M., et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med. 317:1987;669-674.
35. Levy S., Maarek M., Coumel P., Guize L., Lekieffre J., Medvedowsky J.L., et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation. 99:1999;3028-3035.
36. Frykman V., Frick M., Jensen-Urstad M., Ostergren J., Rosenqvist M. Asymptomatic versus symptomatic persistent atrial fibrillation: clinical and noninvasive characteristics. J Intern Med. 250:2001;390-397.
37. Savelieva I., Paquette M., Dorian P., Luderitz B., Camm A.J. Quality of life in patients with silent atrial fibrillation. Heart. 85:2001;216-217.
38. Rose G., Baxter P.J., Reid D.D., McCartney P. Prevalence and prognosis of electrocardiographic findings in middle-aged men. Br Heart J. 40:1978;636-643.
39. Kulbertus H.E., de Leval-Rutten F., Bartsch P., Petit J.M. Atrial fibrillation in elderly, ambulatory patients. Kulbertus H., Olsson S.B., Schlepper M. Atrial fibrillation. 1981;148-157 AB Hassle, Molndal (Sweden).
40. Connolly S.J. Preventing stroke in patients with atrial fibrillation: current treatments and new concepts. Am Heart J. 145:2003;418-423.
41. Peters N.S., Schilling R.J., Kanagaratnam P., Markides V. Atrial fibrillation: strategies to control, combat, and cure. Lancet. 359:2002;593-603.
42. Simek C.L., Feldman M.D., Haber H.L., Wu C.C., Jayaweera A.R., Kaul S. Relationship between left ventricular wall thickness and left atrial size: comparison with other measures of diastolic function. J Am Soc Echocardiogr. 8:1995;37-47.
43. Dittrich H.C., Pearce L.A., Asinger R.W., McBride R., Webel R., Zabalgoitia M., et al. Left atrial diameter in nonvalvular atrial fibrillation: an echocardiographic study. Stroke Prevention in Atrial Fibrillation Investigators. Am Heart J. 137:1999;494-499.
44. Bikkina M., Levy D., Evans J.C., Larson M.G., Benjamin E.J., Wolf P.A., et al. Left ventricular mass and risk of stroke in an elderly cohort. The Framingham Heart Study. JAMA. 272:1994;33-36.
45. Novo S., Barbagallo M., Abrignani M.G., Nardi E., Di Maria G.U., Longo B., et al. Increased prevalence of cardiac arrhythmias and transient episodes of myocardial ischemia in hypertensives with left ventricular hypertrophy but without clinical history of coronary heart disease. Am J Hypertens. 10:1997;843-851.
46. Hennersdorf M.G., Strauer B.E. Arterial hypertension and cardiac arrhythmias. J Hypertens. 19:2001;167-177.
47. Lavie C.J., Ventura H.O., Messerli F.H. Regression of increased left ventricular mass by antihypertensives. Drugs. 42:1991;945-961.
48. Gottdiener J.S. Single-drug therapy and reduction of left ventricular mass in hypertension. Cardiologia. 43:1998;1177-1183.
49. Gottdiener J.S., Reda D.J., Williams D.W., Materson B.J., Cushman W., Anderson R.J. Effect of single-drug therapy on reduction of left atrial size in mild-to-moderate hypertension: comparison of six antihypertensive agents. Circulation. 98:1998;140-148.
50. Dahlof B., Herlitz H., Aurell M., Hansson L. Reversal of cardiovascular structural changes when treating essential hypertension. The importance of the renin-angiotensin-aldosterone system. Am J Hypertens. 5:1992;900-911.
51. Dahlof B., Pennert K., Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies. Am J Hypertens. 5:1992;95-110.
52. Pedersen O.D., Bagger H., Kober L., Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 100:1999;376-380.
53. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 342:2000;145-153.
54. Bosch J., Yusuf S., Pogue J., Sleight P., Lonn E., Rangoonwala B., et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ. 324:2002;699.
55. Madrid A.H., Bueno M.G., Rebollo J.M.G., Marin I., Pena G., Bernal E., et al. Use of Irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation. 106:2002;331-336.